• English
  • Korean
  • Chinese
市場調査レポート - 231632

米国における腫瘍マーカー検査市場の見通し

2014 Strategies for the US Tumor Marker Testing Market

発行 Venture Planning Group
出版日 ページ情報 英文
価格
米国における腫瘍マーカー検査市場の見通し 2014 Strategies for the US Tumor Marker Testing Market
出版日: 2014年01月28日 ページ情報: 英文
概要

当レポートは、米国の腫瘍マーカー検査市場について、経済情勢、規制、人口動態、社会および技術動向が今後10年間に市場に与える影響とともに、病院、研究所、医療機関で利用されている40以上にわたる腫瘍マーカーの売上予測、半自動/自動分析器の設置、インストールベースなどを分析しまとめており、主要企業のプロファイルも織り込んで、概略下記の内容でお届けいたします。

イントロダクション

世界市場と技術概要

  • 癌の統計および病因
    • 乳癌
    • 肺癌
    • 結腸および直腸癌
    • 前立腺癌
    • 胃癌
    • 白血病
    • リンパ癌
    • 口腔癌
    • 皮膚癌
    • 子宮癌
    • 卵巣癌
    • 膀胱癌
  • 主な現在および新興の癌診断検査
    • イントロダクション
    • 腫瘍マーカーの分類
    • ACTH
    • アルファフェトプロテイン(AFP)
    • β2ミクログロブリン
    • CA 15-3/27.29
    • CA 19-9
    • CA-125
    • カルシトニン
    • 癌胎児性抗原(CEA)
    • エストロゲンおよびプロゲステロン受容体
    • フェリチン
    • ガストリン
    • ヒト絨毛性ゴナドトロピン(HCG)
    • インスリン
    • NSE
    • 潜血
    • パップスメア/HPV
    • 前立腺酸性フォスファターゼ(PAP)
    • 前立腺特異抗原(PSA)
    • 扁平上皮癌関連抗原(SCC)
    • TおよびBリンパ球
    • TdT
    • サイログロブリン
    • 組織ポリペプチド抗原(TPA)
    • 生化学腫瘍マーカー
    • 腫瘍遺伝子
    • ポリペプチド増殖因子
    • 異所性ホルモン
    • コロニー刺激因子
    • リンフォカイン
    • 免疫組織化学染色
    • 新興の腫瘍マーカー
  • 装置レビューと市場のニーズ
  • 現行および新興の技術
    • モノクローナルおよびポリクローナル抗体
    • 免疫測定
    • 分子診断
    • 染色体分析
    • 人工知能
    • フローサイトメトリー
    • 二次元ゲル電気泳動(2-DGE)
    • バイオセンサー
    • 競合/補完技術
  • 個別検査

米国市場

  • エグゼクティブサマリー
  • ビジネス環境
    • 医療費
    • コスト意識
    • 償還
    • 業界再編
    • マネージドケア
    • 病院
    • 承認
    • 在院日数
    • 産業多角化
    • 医師統計
    • 人口の高齢化
    • ラボラトリーにおける規制
  • 市場構造
  • 市場規模・成長・主要サプライヤーの販売、機器の設置、市場シェア

主な製品開発の機会

  • 試薬キットおよびテストシステム/パネル
  • 装置
  • コンピューター、ソフトウェア、自動化
  • 補助製品

分散検査製品設計の基準

代替的市場浸透戦略

  • 社内開発
  • 提携契約
  • 大学との提携
  • 流通戦略

市場参入障壁とリスク

  • 市場の成熟
  • 費用抑制
  • 競合
  • 技術力と限界
  • 特許の保護
  • 規制の制限
  • 分散検査市場の課題

競合のプロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Complete report $8,700.  DataPack (test volumes, sales forecasts, supplier shares) $3,450.

Highlights

  • Comprehensive 620-page analysis of the US tumor marker testing market.
  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

  • 1. Brest Cancer
  • 2. Lung Cancer
  • 3. Colon and Rectum Cancer
  • 4. Prostate Cancer
  • 5. Stomach Cancer
  • 6. Leukemia
  • 7. Lymphoma
  • 8. Oral Cancer
  • 9. Skin Cancer
  • 10. Uterine Cancer
  • 11. Ovarian Cancer
  • 12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

  • 1. Introduction
  • 2. Tumor Marker Classification
  • 3. ACTH
  • 4. Alpha-Fetoprotein (AFP)
  • 5. Beta-2 Microglobulin
  • 6. CA 15-3/27.29
  • 7. CA 19-9
  • 8. CA-125
  • 9. Calcitonin
  • 10. Carcinoembrionic Antigen (CEA)
  • 11. Estrogen and Progesterone Receptors
  • 12. Ferritin
  • 13. Gastrin
  • 14. Human Chorionic Gonadotropin (HCG)
  • 15. Insulin
  • 16. NSE
  • 17. Occult Blood
  • 18. PAP Smear/HPV
  • 19. Prostatic Acid Phosphatase (PAP)
  • 20. Prostate-Specific Antigen (PSA)
  • 21. Squamous Cell Carcinoma Antigen (SCC)
  • 22. T and B Lymphocytes
  • 23. TdT
  • 24. Thyroglobulin
  • 25. Tissue Polypeptide Antigen (TPA)
  • 26. Biochemical Tumor Markers
    • ADA
    • B-Protein
    • PNP
    • 5'-Nucleotidase
  • 27. Oncogenes
    • Abl/abl-bcr
    • AIB1
    • BCL-2
    • BRCA1
    • CD44
    • C-fos
    • C-myb
    • C-myc
    • CYP-17
    • Erb-B
    • HPC1
    • N-myc
    • P40
    • P51
    • P53
    • PIK3CA
    • PTI-1
    • Ras
    • Reg
    • Sis
    • Src
  • 28. Polypeptide Growth Factors
  • Basic Fibroblast Growth Factor
    • Beta-TGF
    • Cachectin (TNT)
    • Calmodulin
    • ECFR
    • Nerve Growth Factor (NGF)
    • Epidermal Growth Factor (EGF)
    • Ornithine Decarboxylase
    • Transferrin
    • Transforming Growth Factor-Alpha
  • 29. Ectopic Hormones
  • 30. Colony Stimulating Factors
  • 31. Lymphokines
    • Alpha-Interferon
    • B Cell Growth Factors
    • B Cell Growth Factor (BCGF)
    • Gamma-Interferon
    • Interleukin-1 (IL-1)
    • Macrophage Activating Factor
  • 32. Immunohistochemical Stains
  • 33. Emerging Tumor Markers
    • N-Acetylglucosamine
    • Actin
    • Alpha-Actin
    • Antineuronal Antibodies
    • 7B2
    • B72.3
    • Bax
    • BCD-F9
    • BLCA-4
    • Blood Group Antigens A,B,H
    • CA 50
    • CA 72-4/TAG-72
    • CA 195
    • CA-242
    • CA-549
    • CAM 26
    • CAR-3
    • Cathepsin-D
    • Chromogranin A and B
    • Cluster 1 Antigen
    • Cluster-5/5A Antigen
    • CTA
    • CU18
    • DR-70
    • DU-PAN-2
    • Endometrial Bleeding Associated Factor
    • Endostatin
    • Epithelial Membrane Antigen
    • Feulgen Hydrolysis
    • Fibronectin
    • FSH
    • (1->3)-L-fucosyltransferase
    • Gastrin-Releasing Peptide (GRP)
    • GDCFP-15
    • Glucagon
    • Glycoamines
    • H23
    • Her-2
    • Human Carcinoma Antigen
    • HPA
    • HSP27
    • Intermediate Filaments
    • Cytokeratins/CK18/Cyfra 21-1
    • Desmin
    • Gliofibrillary Acid Protein
    • Neurofilaments
    • Vimentin
    • KA 93
    • Kinases
    • KP16D3
    • LAI
    • Leukocyte Common Antigen
    • Lewis Antigens
    • Lysophosphatidic Acid (LPA)
    • Ma 695/Ma 552
    • MABDF3
    • MAG
    • ME1
    • Minactivin
    • MN/CA9
    • MSA
    • Mucin Cancer Antigen (MCA)
    • Multiple Tumor Suppressor 1
    • Myosin
    • NEA-130
    • NMP22
    • OA-519
    • Opiod Peptides
    • P-glycoprotein
    • Pancreatic Oncofetal Antigen (POA)
    • Placental Lactogen
    • PR92
    • Proliferative Index, Ki-67
    • Px
    • RB Inactivation/Deletion
    • Ret
    • SCCL 175
    • Selectin
    • Sialic Acid
    • Sialyl SSEA-1/SLX
    • SN10
    • Somatostatin
    • TA-90
    • TABA
    • Tachykinin
    • TAG 12
    • TPS
    • Troponin
    • Tubulin
    • VCAM
    • VEGF
    • Villen

C. Instrumentation Review And Market Needs

  • 1. Abbott AxSYM
  • 2. Abbott Architect c4000
  • 3. Abbott Architect i2000 Series
  • 4. Abbott Architect ci8200 System
  • 5. Beckman Coulter UniCel Series
  • 6. Beckman Coulter Access
  • 7. Binding Site ESP600
  • 8. bioMerieux Mini Vidas
  • 9. Carolina Chemistries BioLis 24i
  • 10. DiaSorin Liaison
  • 11. Horiba ABX Pentra 400
  • 12. Inverness DS2
  • 13. J&J Vitros ECi/ECiQ
  • 14. J&J Vitros 3600
  • 15. J&J Vitros 5600
  • 16. Olympus AU5400
  • 17. Olympus AU3000i
  • 18. Olympus AU2700
  • 19. Roche Modular Analytics
  • 20. Roche Cobas Integra 400
  • 21. Roche Cobas Integra 400 Plus
  • 22. Roche Elecsys
  • 23. Roche Cobas c311
  • 24. Siemens ADVIA Centaur
  • 25. Siemens Dimension
  • 26. Siemens Dimension RxL Max
  • 27. Siemens Dimension Vista 500
  • 28. Siemens Immulite
  • 29. Siemens Stratus
  • 30. Tosoh AIA-Series
  • 31. Vital Diagnostics ATAC 8000
  • 32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

  • 1. Monoclonal and Polyclonal Antibodies
  • 2. Immunoassays
    • a. Technological Principle
    • b. Radioimmunoassay (RIA)
    • c. Enzyme Immunoassays (EIA)
      • Overview
      • ELISA
      • Immunofiltration
      • Particle-Membrane Capture Immunoassay
      • Enzyme Amplification
    • d. Fluorescent Immunoassays
    • e. Luminescence
      • Chemiluminescence
      • Bioluminescence
    • f. Latex Agglutination
    • g. Immunoprecipitation
    • H. Affinity Chromatographu
    • e. Liposome Flow-Injection Immunoassay
  • 3. Molecular Diagnostics
    • a. Technology Overview
    • b. Amplification Methods
      • PCR
      • DAP-PCR
      • Immuno-PCR
      • QC-PCR
      • CAR
      • DNA
      • HPA
      • LCR
      • NASBA
      • QBR
      • SDA
      • 3 SR, and others
  • 4. Chromosome Analysis
    • a. Chronic Myelogenous Leukemia (CML)
    • b. Acute Myeloid Leukemia (AML)
    • c. Acute Lymphoblastic Leukemia (ALL)
    • d. Malignant Lymphomas
    • Lymphoid Malignancies
    • e. Chronic Lymphocytic Leukemia (CLL)
    • f. Solid Cancers
    • g. Chromosomal Translocation and Oncogenes
  • 5. Artificial Intelligence
  • 6. Flow Cytometry
  • 7. Two Dimensional Gel Electrophoresis (2-DGE)
  • 8. Biosensors
  • 9. Competing/Complementing Technologies
    • a. CT
    • b. MRI
    • c. NMR
    • d. PET
    • e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

  • A. Executive Summary
  • B. Business Environment
  • 1. Health Care Expenditures
  • 2. Cost Consciousness
  • 3. Industry Consolidation
  • 4. Managed Care
  • 5. Hospitals
  • 6. Admissions
  • 7. Length of Stay
  • 8. Industry Diversification
  • 9. Physician Demographics
  • 10. Population Aging
    • a. Chronic Illness
    • b. Disease Incidence
    • c. Susceptibility to Iatrogenesis
    • d. Multiple Illness Cases
  • 11. Laboratory Regulations

C. Market Structure

  • 1. Centralized Testing
    • a. Hospitals
    • b. Commercial/Private Laboratories
  • 2. POT/Decentralized Testing
    • a. Physician Offices/Group Practices
    • b. Cancer Clinics
    • c. Point-Of-Care Testing
    • d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

Competitive Profiles

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

Appendixes

  • Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
  • Appendix II: Assumed Currency Exchange Rates

List of Tables

  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications In Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
  • Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by Market Segment
  • U.S., Estimated New Cancer Cases and Deaths
  • U.S., Estimated Cancer Death Rates Per 100,000 Population
  • U.S., Laboratories Performing Tumor Marker Tests by Market Segment
  • U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
  • U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume
  • U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size
  • U.S., Total Tumor Marker Test Volume Forecast by Market Segment-201
  • U.S., All Market Segments Major Tumor Marker Test Volume Forecast
  • U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
  • U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
  • U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
  • U.S., Total Tumor Marker Sales Forecast by Market Segment
  • U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
  • U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
  • U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
  • U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Beta-2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CEA Test Volume and Diagnostics Sales by Market Segment
  • U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Colon-specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Total Tumor Marker Sales By Major Supplier
  • U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
  • U.S., AFP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CEA Testing Market Diagnostics Sales by Major Supplier
  • U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
  • U.S., HCG Testing Market Diagnostics Sales by Major Supplier
  • U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
  • U.S., PAP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
  • U.S., PSA Testing Market Diagnostics Sales by Major Supplier
Back to Top